{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:27:09Z","timestamp":1785518829676,"version":"3.56.0"},"reference-count":106,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BeiGene, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Marginal zone lymphomas (MZL) are a rare, heterogenous group of lymphomas, accounting for 5\u201317% of indolent non-Hodgkin lymphomas in the western world. They can be further divided into three subtypes: extranodal MZL, splenic MZL, and nodal MZL. These subtypes differ in clinical presentation and behavior, which influences how they are managed. There is currently no standard of care for the treatment of MZL, owing to the difficulty in conducting phase 3 randomized trials in MZL, and the fact that there are limited data on the efficacy of therapy in individual subtypes. Treatment practices are thus largely borrowed from other indolent lymphomas and are based on patient and disease characteristics, as well as access to therapy. This review summarizes the Canadian treatment landscape for MZL and how these therapies may be sequenced in practice.<\/jats:p>","DOI":"10.3390\/curroncol30020135","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T05:57:56Z","timestamp":1675231076000},"page":"1745-1759","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Management of Marginal Zone Lymphoma: A Canadian Perspective"],"prefix":"10.3390","volume":"30","author":[{"given":"Anthea","family":"Peters","sequence":"first","affiliation":[{"name":"Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Margaret","family":"Keating","sequence":"additional","affiliation":[{"name":"Division of Hematology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS B3H 2Y9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3255-0472","authenticated-orcid":false,"given":"Anna","family":"Nikonova","sequence":"additional","affiliation":[{"name":"Division of Hematology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Doucette","sequence":"additional","affiliation":[{"name":"Impact Medicom Inc., Toronto, ON M6S 3K2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Prica","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.beha.2016.07.002","article-title":"Epidemiology and environmental aspects of marginal zone lymphomas","volume":"30","author":"Sriskandarajah","year":"2017","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.beha.2016.08.025","article-title":"Marginal zone lymphoma in elderly and geriatric patients","volume":"30","author":"Goede","year":"2017","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-28","article-title":"Epidemiology of marginal zone lymphoma","volume":"5","author":"Cerhan","year":"2021","journal-title":"Ann. Lymphoma"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Di Rocco, A., Petrucci, L., Assanto, G.M., Martelli, M., and Pulsoni, A. (2022). Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment. Cancers, 14.","DOI":"10.3390\/cancers14071742"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.2021.278755","article-title":"Marginal zone lymphoma: Present status and future perspectives","volume":"107","author":"Cheah","year":"2022","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.2019001088","article-title":"Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study","volume":"134","author":"Luminari","year":"2019","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00428-022-03432-2","article-title":"Follicular lymphoma and marginal zone lymphoma: How many diseases?","volume":"482","author":"Laurent","year":"2023","journal-title":"Virchows Archiv."},{"key":"ref_9","unstructured":"Jaffe, E.S., Harris, N.L., Stein, H., and Vardiman, J.W. (2001). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3816\/CLM.2005.n.003","article-title":"Clinicopathologic features of Waldenstr\u00f6m\u2019s macroglobulinemia and marginal zone lymphoma: Are they distinct or the same entity?","volume":"5","author":"Berger","year":"2005","journal-title":"Clin. Lymphoma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.2006.06.0723","article-title":"Assessment of Disease Dissemination in Gastric Compared With Extragastric Mucosa-Associated Lymphoid Tissue Lymphoma Using Extensive Staging: A Single-Center Experience","volume":"24","author":"Raderer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bjhh.2016.09.014","article-title":"Splenic marginal zone lymphoma: A literature review of diagnostic and therapeutic challenges","volume":"39","author":"Santos","year":"2017","journal-title":"Rev. Bras. de Hematol. e Hemoter."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood-2022-158771","article-title":"Impact of Monoclonal Protein at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma: A Multicenter Cohort Study","volume":"140","author":"Epperla","year":"2022","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/CCO.0b013e328349ab8d","article-title":"Splenic marginal zone B-cell lymphoma: A distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification","volume":"23","author":"Baseggio","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.thromres.2014.08.021","article-title":"Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma","volume":"134","author":"Gebhart","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood.2019002762","article-title":"Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis","volume":"135","author":"Basset","year":"2020","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3988\/jcn.2015.11.3.283","article-title":"Autoantibody-Mediated Sensory Polyneuropathy Associated with Indolent B-Cell Non-Hodgkin\u2019s Lymphoma: A Report of Two Cases","volume":"11","year":"2015","journal-title":"J. Clin. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3324\/haematol.2012.083386","article-title":"Recognizing nodal marginal zone lymphoma: Recent advances and pitfalls. A systematic review","volume":"98","year":"2013","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.leukres.2016.03.005","article-title":"Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era","volume":"44","author":"Perrone","year":"2016","journal-title":"Leuk Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1055\/a-0859-7737","article-title":"Patients with gastric MALT lymphoma revealing persisting endoscopic abnormalities after successful eradication of Helicobacter pylori can be safely managed by a watch-and-wait strategy","volume":"57","author":"Fischbach","year":"2019","journal-title":"Z. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/bloodadvances.2020003213","article-title":"Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue","volume":"5","author":"Joffe","year":"2021","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"965727","DOI":"10.3389\/fonc.2022.965727","article-title":"Surgery and chemotherapy cannot improve the survival of patients with early-stage mucosa-associated lymphoid tissue derived primary pulmonary lymphoma","volume":"12","author":"Lin","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/annonc\/mdp402","article-title":"Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: Results from a population-based study on extranodal marginal zone lymphomas","volume":"21","author":"Luminari","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199405053301803","article-title":"Helicobacter pylori Infection and Gastric Lymphoma","volume":"330","author":"Parsonnet","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/ajg.2009.314","article-title":"Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: A pooled data analysis","volume":"104","author":"Zullo","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e12774","DOI":"10.1111\/hel.12774","article-title":"Efficacy of eradication therapy in Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: A meta-analysis","volume":"26","author":"Jung","year":"2021","journal-title":"Helicobacter"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/CM9.0000000000000813","article-title":"Clinical efficacy of the modified Helicobacter pylori eradication therapy for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: A meta analysis","volume":"133","author":"Xie","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/gast.2002.33047","article-title":"T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication","volume":"122","author":"Liu","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/djj373","article-title":"Bacteria-Eradicating Therapy With Doxycycline in Ocular Adnexal MALT Lymphoma: A Multicenter Prospective Trial","volume":"98","author":"Ferreri","year":"2006","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/path.1984","article-title":"Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions","volume":"209","author":"Chanudet","year":"2006","journal-title":"J. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.leukres.2005.09.012","article-title":"Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci? The University of Rochester experience","volume":"30","author":"Vargas","year":"2006","journal-title":"Leuk Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.leukres.2007.10.013","article-title":"Chlamydia psittaci in MALT lymphomas of ocular adnexals: The Austrian experience","volume":"32","author":"Aigelsreiter","year":"2008","journal-title":"Leuk Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-9378-7-8","article-title":"Chlamydia psittaci in ocular adnexa MALT lymphoma: A possible role in lymphomagenesis and a different geographical distribution","volume":"7","author":"Collina","year":"2012","journal-title":"Infect. Agents Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40588-018-0108-8","article-title":"Chlamydia psittaci in Ocular Adnexal MALT Lymphoma: A Possible Causative Agent in the Pathogenesis of This Disease","volume":"5","author":"Aigelsreiter","year":"2018","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0046-8177(00)80233-6","article-title":"Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin","volume":"31","author":"Roggero","year":"2000","journal-title":"Hum. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0190-9622(97)80405-7","article-title":"Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: Complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a","volume":"36","author":"Bonsmann","year":"1997","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa031887","article-title":"Immunoproliferative Small Intestinal Disease Associated with Campylobacter jejuni","volume":"350","author":"Lecuit","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"888","DOI":"10.7326\/0003-4819-89-6-888","article-title":"Increased risk of lymphoma in sicca syndrome","volume":"89","author":"Kassan","year":"1978","journal-title":"Ann. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood.V90.2.766","article-title":"Lymphomas in Patients With Sj\u00f6gren\u2019s Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses","volume":"90","author":"Royer","year":"1997","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","article-title":"Malignant lymphoma in primary Sj\u00f6gren\u2019s syndrome: A multicenter, retrospective, clinical study by the European concerted action on Sj\u00f6gren\u2019s syndrome","volume":"42","author":"Voulgarelis","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/00000478-200005000-00001","article-title":"Malignant lymphoma of the thyroid gland: A clinicopathologic study of 108 cases","volume":"24","author":"Derringer","year":"2000","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000502204","article-title":"Mucosa-Associated Lymphoid Tissue Lymphoma of the Thyroid Gland: A Systematic Review of the Literature","volume":"9","author":"Karvounis","year":"2020","journal-title":"Eur. Thyroid J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood-2002-10-3230","article-title":"Hepatitis C virus and B-cell non-Hodgkin lymphomas: An Italian multicenter case-control study","volume":"102","author":"Mele","year":"2003","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/sj.leu.2403443","article-title":"Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas","volume":"18","author":"Kelaidi","year":"2004","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: A study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/bloodadvances.2020003992","article-title":"Involved-site radiotherapy for Helicobacter pylori\u2013independent gastric MALT lymphoma: 26 years of experience with 178 patients","volume":"5","author":"Yahalom","year":"2021","journal-title":"Blood Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","article-title":"Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy","volume":"116","author":"Goda","year":"2010","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/hed.24717","article-title":"Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma","volume":"39","author":"Pinnix","year":"2017","journal-title":"Head Neck"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"20210012","DOI":"10.1259\/bjr.20210012","article-title":"Efficacy of low-dose radiotherapy (2 Gy \u00d7 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas","volume":"94","author":"Cerrato","year":"2021","journal-title":"Br. J. Radiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 60 patients","volume":"100","author":"Mollejo","year":"2002","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.13320","article-title":"Outcomes in splenic marginal zone lymphoma: Analysis of 107 patients treated in British Columbia","volume":"169","author":"Xing","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1634\/theoncologist.2012-0251","article-title":"Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy","volume":"18","author":"Kalpadakis","year":"2013","journal-title":"Oncologist"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","article-title":"Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment","volume":"55","author":"Lenglet","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3109\/10428194.2015.1092529","article-title":"Peri-operative complications and hematologic improvement after first-line splenectomy for splenic marginal zone lymphoma","volume":"57","author":"Pata","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: From genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428190701457949","article-title":"Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma","volume":"48","author":"Lossos","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000074641","article-title":"Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma","volume":"65","author":"Raderer","year":"2003","journal-title":"Oncology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"key":"ref_63","first-page":"856","article-title":"Rituximab monotherapy for splenic marginal zone lymphoma","volume":"90","author":"Bennett","year":"2005","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma: Prolonged responses and potential benefit from maintenance","volume":"132","author":"Kalpadakis","year":"2018","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study","volume":"35","author":"Rummel","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","article-title":"Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma","volume":"130","author":"Salar","year":"2017","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.15641","article-title":"Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: Results from the phase II BRISMA\/IELSG36 study","volume":"183","author":"Iannitto","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.24605","article-title":"Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type","volume":"115","author":"Salar","year":"2009","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2141.2009.07677.x","article-title":"A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas","volume":"145","author":"Brown","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2018.36.15_suppl.7515","article-title":"Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial)","volume":"36","author":"Rummel","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/10428190902730219","article-title":"Infectious complications of rituximab in patients with lymphoma during maintenance therapy: A systematic review and meta-analysis","volume":"50","author":"Aksoy","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/2643-3230.BCD-21-0222","article-title":"CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity","volume":"3","author":"Shree","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/bloodadvances.2021004629","article-title":"Vaccine response following anti-CD20 therapy: A systematic review and meta-analysis of 905 patients","volume":"5","author":"Vijenthira","year":"2021","journal-title":"Blood Adv."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: An open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2016-06-720599","article-title":"A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma","volume":"129","author":"Kiesewetter","year":"2017","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","article-title":"First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_82","unstructured":"United States Food & Drug Administration (2022, December 23). FDA Investigating Possible Increased Risk of Death with Lymphoma Medicine Ukoniq (umbralisib), Available online: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-investigating-possible-increased-risk-death-lymphoma-medicine-ukoniq-umbralisib."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","article-title":"Obinutuzumab (GA101) in Patients With Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase II GAUGUIN Study","volume":"31","author":"Salles","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: Long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed\/Refractory Marginal Zone Lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2022-163371","article-title":"Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed\/Refractory (R\/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial","volume":"140","author":"Opat","year":"2022","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: The ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1182\/blood.V126.23.3973.3973","article-title":"AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma)","volume":"126","author":"Kiesewetter","year":"2015","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a Dual PI3K\u03b4\/CK1\u03b5 Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00432-021-03833-x","article-title":"Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: A narrative review with focus on diffuse large B-cell lymphoma","volume":"148","author":"Zinzani","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for Stage I-II follicular lymphomas","volume":"51","author":"Wilder","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1200\/jco.2004.22.90140.6521","article-title":"Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone","volume":"22","author":"Petersen","year":"2004","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/2\/135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:21:06Z","timestamp":1760120466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/2\/135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":106,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["curroncol30020135"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30020135","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}